Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Stopped A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Conditions
- Advanced Solid Tumors
- MSI-H/dMMR Tumors
- Cutaneous Squamous Cell Carcinoma
- Urothelial Carcinoma, HCC
- Cervical Cancer
- Esophageal Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Small-cell Lung Cancer
- Mesothelioma
- PD-L1 Amplified Tumor (9p24.1)
- Nasopharyngeal Carcinoma
- Cyclin-dependent Kinase 12 Mutated Tumors
- Basal Cell Carcinoma (Unresectable or Metastatic)
- Sarcomatoid Renal Cell Carcinoma
- Clear Cell Ovarian or Endometrial Carcinoma
- Anal Carcinoma
- Squamous Cell Penile Carcinoma
- DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)
Interventions
Sponsor
Incyte Corporation